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Resumo 
Introdução: A síndrome da fragilidade é comum na esteno aórtica (EA), 
atingindo de 30 a 50% dos pacientes com EA grave. Essa síndrome tem sido 
associada à inflamação, à resistência à insulina, à resposta deficiente à glicose 
e à baixa percentagem de massa magra, características normalmente 
presentes na obesidade central. O ângulo de fase (AF) é um parâmetro 
derivado da análise de impedância bioelétrica (BIA), e seu valor reflete a 
integridade da membrana celular, sendo afetado pela inflamação e pelo estado 
nutricional. Pouco se sabe sobre a contribuição da distribuição de adiposidade 
na fragilidade, e sobre as influências de fragilidade e da obesidade visceral no 
valor do PA. 
Objetivos: Avaliar a existência de associações entre fragilidade, depósitos de 
gordura visceral e AF em pacientes com EA grave. 
Métodos: Em uma coorte de pacientes com EA grave referidos para cirurgia de 
substituição da válvula aórtica, a presença de fragilidade foi avaliada através da 
escala de Fried et al. Os valores do AF e da composição corporal dos 
pacientes foram obtidos a partir da avaliação de BIA [composição corporal 
dada em % de massa gorda (%MG) e % de massa magra (%MM)]. Utilizou-se 
tomografia computadorizada para a quantificação das gorduras: tecido adiposo 
epicárdico (TAE) e mediastínico (TAM), e gorduras abdominal total (GAT), 
visceral (GAV) e subcutânea (GAS). As medidas de adiposidade foram 
indexadas para a área de superfície corporal. Foram criados dois grupos: 
frágeis e não-frágeis, estando incluídos no último grupo os pacientes 
classificados como não frágeis e pré-frágeis. Outras medidas antropométricas 
avaliadas foram: índice de massa corporal (IMC), circunferências da cintura 
(CC) e do quadril (CQ) e relação CC/CQ. 
Resultados: Cinquenta e cinco pacientes foram incluídos no estudo (73±9 
anos, IMC = 29±5 kg/m², 57% do sexo masculino). A prevalência de fragilidade 
foi de 47%. Ajustando para idade e sexo, a fragilidade foi significativamente 
associada com o volume indexado de TAE (p = 0,042) e AF (p = 0,03), mas 
não com IMC, %FM e %FFM, CC, GAT, GAV ou GAS. Num modelo também 
ajustado para idade e sexo, o AF apresentou correlação inversa com a relação 
CC/CQ (p=0,02), %FM (p=0,02) e com o volume indexado de TAE (p=0,03), 
mas não com o IMC, % FFM, TAM indexado e áreas de GAV, GAS e GAT. 
Conclusões: Em pacientes com EA grave, TAE é um preditor independente de 
fragilidade, o que não se verifica com o IMC ou com outros depósitos de 
gordura. Além disso, a fragilidade e o TAE parecem estar associados com 
redução da integridade da membrana celular, a qual foi avaliada através do AF. 
Palavras-chave: fragilidade, tecido adiposo visceral, tecido adiposo epicárdico, 
ângulo de fase, estenose aórtica. 
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Abstract 
Background: Frailty syndrome is common in aortic stenosis (AS), reaching 30-
50% in the severe form of the disease. Frailty has been linked to increased 
inflammation, insulin resistance, impaired response to glucose exposure and 
low percentage of fat free mass, characteristics usually present in central 
obesity. Phase angle (PA) is a value derived from bioelectrical impedance 
analysis (BIA) that reflects cell membrane integrity and function, being affected 
by inflammation and nutritional status. Few studies are available on the relative 
contribution of adiposity distribution on frailty, and about the influences of frailty 
and visceral obesity in PA value. 
 Aims: To evaluate associations among frailty, visceral fat depots and PA in 
patients with symptomatic severe AS. 
Methods: In a cohort of patients with severe AS referred to aortic valve 
replacement (AVR), we used Fried et al. scale to evaluate frailty syndrome, and 
BIA to obtain PA and body composition [given in % fat mass (%FM) and % fat 
free mass (%FFM)]. Multidetector computed tomography was performed to 
quantify the following adipose tissues: epicardial (EAT), mediastinal (MAT) and 
total (TAF), visceral (VAF) and subcutaneous abdominal fat (SAF). We created 
two groups: frail and non-frail, the latter group including patients classified as 
intermediate or robust. Other anthropometric measurements were performed: 
body mass index (BMI), waist (WC) and hip circumferences (HC), WC/HP ratio. 
Results: We included fifty-five patients (73±9 years, BMI=29±5 kg/m², 57% 
males). The prevalence of frailty was 47%. Adjusting for age and gender, frailty 
was associated with indexed EAT volume (p=0.042) and PA (p=0.03), but not 
with BMI, %FFM and %FM, WC, TAF, VAF or SAF. In an age and gender 
adjusted model, PA was inversely correlated with WC/HC ratio (p=0.02), %FM 
(p=0.02) and indexed EAT volume (p=0.03), but not with BMI, WC, %FFM, 
indexed MAT, VAF, SAF and TAF areas. 
Conclusions: In patients with severe AS referred to AVR, EAT is an 
independent predictor of frailty, but not BMI or other fat depots. Moreover, frailty 
and EAT appear to be associated with impaired cell membrane integrity and 
function assessed by BIA derived PA.  
Keywords: frailty, visceral adipose tissue, epicardial adipose tissue, phase 
angle, aortic stenosis. 
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1. Introduction 
Frailty is a geriatric syndrome characterized by accelerated decline in 
physiological reserves and failure of homeostatic mechanisms(1). Consequently, 
there is a decreased responsiveness capacity of many physiological systems 
and increased vulnerability to stressful events(2-4). This phenotype is associated 
with higher risks of adverse outcomes related to health in older people, such as 
increased mortality, morbidity, number of falls and hospitalizations, and reduced 
activities of daily living(2, 5). 
Frailty prevalence has increased in western world given population 
aging, ranging from 7 to 12% in older adults (aged ≥ 65 years) in the United 
States(2), and 17% in Europe(6). Although frailty syndrome can occur 
independently of a medical condition, its prevalence clearly increases in 
subjects with cardiovascular disease. In patients with aortic stenosis (AS), the 
prevalence of frailty reaches 30-50% when the severe form of the disease is 
present(7, 8). 
1.1. Frailty pathophysiology 
The pathophysiology of frailty has been imprecise and variously 
descripted. However, it is generally accepted that, in frailty, the gradual decline 
in physiological reserve associated with ageing is accelerated and the 
homeostatic mechanisms start failing early(1). Beyond ageing, this syndrome 
arises as consequence of sedentary lifestyle, nutritional disorders, comorbidities 
and diseases. 
A cumulative decline occurs in different physiologic systems, 
especially the skeletal muscle system(2), endocrine system (cortisol, estrogen, 
testosterone)(9, 10), immunological system (inflammation)(11) and neurologic 
system(12).  
This imbalance in organic central systems gives rise a chronic 
inflammatory process, and frailty has significant association with elevated 
interleukin 6, white blood cell and reactive C-protein levels(13, 14). The increase in 
proinflammatory cytokines is associated with lower muscle strength, lower 
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physical performance and higher risk of disability in older persons(15), 
characteristics commonly used in models to measure frailty. Hence, the degree 
of inflammatory load appears to be parallel to the degree of frailty.  
1.2. Frailty phenotype and obesity  
Models of frailty try to measure deficiencies in domains of functioning 
(physical, nutritive, cognitive, and sensory)(16) or deficit accumulation related to 
diseases, symptoms, conditions and disability(17). 
In a landmark study, Fried et al.(2) defined the most well-known and 
widely used phenotype model of frailty, which is based on five variables: 
unintentional weight loss; self-reported exhaustion; low energy expenditure; 
slow gait speed and weak grip strength. The presence of three or more criteria 
characterizes frailty. 
The inclusion of weight loss in frailty criteria is congruent with the 
conceptualization of frailty as a wasting disorder, with sarcopenia as the major 
feature. However, obesity in older people is associated with greater risk of 
impaired physical function, which is closely intertwined with frailty. In addition, 
obesity, in particular the visceral obesity, induces a chronic proinflammatory 
state(18, 19), which has been also associated with frailty, as previously described. 
Beyond chronic inflammation(20), studies associate frailty syndrome 
with insulin resistance(21) (especially in the presence of increased abdominal 
fat(22)), deregulated response to glucose exposure(23) and low percentage of fat 
free mass (FFM)(24). Although adipose tissue has been associated with frailty, it 
is not yet clearly established whether the different adipose compartments 
(visceral abdominal fat, subcutaneous abdominal fat, epicardial adipose tissue, 
myocellular and intermuscular adipose tissue) contribute in the same way to the 
presence of frailty. Moreover, despite the well-established knowledge about the 
negative changes in health associated with altered body fat distribution, there 
remains a lack of knowledge on interrelationships among these fat 
compartments and frailty in elderly populations. 
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1.3. Frailty and phase angle as cellular damage biomarker 
The Fried et al. phenotype model of frailty includes both objective 
and subjective factors, but not a biomarker of frailty. Presently there is not 
enough data to separate the degrees of frailty (non-frail, pre-frail, frail) in 
different settings of elderly persons. Beyond the diagnosis of frailty, the 
identification of biomarkers is of great interest mainly for the follow-up of this 
syndrome course and also to monitor possible therapeutic interventions. 
Bioelectrical impedance analysis (BIA) is a technique based in the 
bioelectrical properties of tissues and measures the cell membrane resistance 
to an electrical current passing through the body: the capacitative resistance 
(called reactance, Xc), and the resistive resistance (simply called resistance, R). 
Capacitance arises from cell membranes and R from extra and intracellular 
fluid, and the combination of both is called impedance(25).  
The relationship between Xc and R reflects different electrical 
properties of tissues that change in different ways by disease, nutritional and 
hydration status(25). The phase angle (PA), which is one measure of this 
relationship, is the angle between impedance vector and the R vector, and it is 
calculated in degrees by the formula: arc tangent (Xc/R)*180/(26). PA’s values 
reflect cell membrane integrity and function by a direct correlation: the higher 
the PA’s value, the greater the amount of intact cell membranes and body cell 
mass(26).  
This BIA derived parameter varies with gender and body mass index 
(BMI), tending to decline with age(27). Nutritional status(28, 29), disease, 
inflammation, infection or prolonged physical inactivity can result in disturbed 
electrical properties of tissues that directly affect the PA(30). Many studies also 
underline the utility of PA as a marker of impaired clinical outcome and mortality 
in populations with chronic disease(31-33), and its correlation with membrane 
function enables earlier insight into disturbances of health and responses to 
pharmacological and other clinical interventions compared to the other levels of 
testing(30). 
Therefore, we hypothesized that visceral obesity might be involved in 
the pathophysiology of global inflammatory process and cellular senescence 
present in frailty syndrome, and that PA might be used as a marker of this 
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potential link between visceral obesity and frailty. First, we determined if and 
how the body fat distribution was associated with the presence of frailty in 
patients with severe aortic stenosis who were referred to multidectector 
computed tomography (MDCT) before aortic valve replacement (AVR). Second, 
we assessed the association of PA with frailty and with each fat compartment. 
In the long term, we expect to evaluate the influence of visceral fat in frailty 
classification and PA’s value changes after AVR.  
2. Objectives 
In a cohort of patients with severe symptomatic AS and preserved 
ejection fraction referred to MDCT before AVR, our main aims are to explore the 
association of visceral adiposity and frailty and to assess if preoperative PA 
determination could contribute to a better evaluation of frailty in this patient 
population. Our specific aims are: 
Specific aim 1: To study the association of frailty with epicardial adipose 
tissue (EAT), mediastinal adipose tissue (MAT) and abdominal fat [total 
(TAF); visceral (VAF) and subcutaneous (SAF)] in patients with severe AS. 
In a cross-sectional design, we determined, using a multivariable logistic 
regression model including age, gender and body surface area, the 
independent association of frailty, according to Fried et al.(2) classification, with 
the preoperative amount of EAT, MAT, VAF and SAF quantified by MDCT.  
Specific aim 2: To determine if BIA derived phase angle independently 
correlates with frailty in patients with severe AS. In a cross-sectional design, 
we evaluated the age and gender adjusted association of frailty with the PA 
values using a multivariable logistic regression model.  
Specific aim 3: To evaluate if visceral obesity is associated with impaired 
cell membrane integrity assessed by BIA derived PA. In a cross-sectional 
design, we determined, using a multivariable linear regression model including 
age, gender and body surface area, the adjusted correlation of PA and the 
preoperative amount of EAT, MAT and VAF. 
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3. Methods 
3.1. Study design and population 
In order to determine the association of frailty syndrome with visceral 
obesity in patients with symptomatic severe AS referred to AVR, we conducted 
an observational cross-sectional, single center study at the Centro Hospitalar 
Vila Nova de Gaia e Espinho-EPE.  
Patients were eligible if they were over 18 years of age, presented 
with symptoms on exertion, aortic valve area ≤0.8 cm² and if they had the ability 
to read and provide a written informed consent.  
Exclusion criteria were: (1) moderate to severe aortic valve 
regurgitation, (2) moderate to severe mitral valve disease, (3) bicuspid aortic 
valve, (4) left ventricular (LV) dilatation [according to American Society of 
Echocardiography (ASE) guidelines (34): LV end-diastolic volume index >75 
mL/m², to women and men], (5) LV ejection fraction depression (according to 
ASE guidelines: LV ejection fraction <55%, to men and women), (6) paroxysmal 
or permanent atrial fibrillation, (7) permanent pacemaker, (8) previous cardiac 
surgery, (9) previous infectious endocarditis, (10) chronic renal failure stage 3 to 
5, and (11) moderate to severe chronic pulmonary disease. 
At the preoperative period, patients were evaluated using a validated 
frailty scale, clinical interview, nutritional assessment including anthropometric 
and bioimpedance analyses, echocardiogram, multidetector computed 
tomography (MDCT) and laboratory blood tests.  
The institutional and national ethics committee of biomedical 
research approved the present study. We informed the patients about the 
purpose of the study and each enrolled patient signed an informed consent. 
The study activities description is accessible in Table 1. 
3.2. Frailty Scale 
We used Fried et al.’s Frailty Scale (2) to classify the patients into 
three groups: participants meeting 3 or more criteria were classified as frail; 
those meeting 1 or 2 as intermediate; and those meeting none as robust. This 
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scale is based on six parameters: (1) unintentional weight loss; (2) exhaustion; 
(3) adductor pollicis muscle thickness, which was measured with a precision of 
0.2 mm, using a calliper (John Bull, British Indicators Ltd, England); (4) hand 
grip strength, measured to the nearest 0.5 kg, using a mechanical 
dynamometer Smedlay (Smedlay, TTM, Tokyo, Japan); (5) walking speed, 
measured in seconds using a digital stopwatch; and (6) level of energy 
expenditure related to physical activity, measured by the Minnesota Leisure 
Time Activity Questionnaire(35). 
During grip strength measurement, patients were positioned 
according to the American Society of Hand Therapists’ recommendations(36), 
and instructed to apply as much pressure as they could handle. The 
measurement was performed in the dominant hand and the final value was the 
average of three measurements. 
3.3. Nutritional assessment 
The nutritional evaluation consisted in (1) anthropometric 
measurements and (2) bioelectrical impedance analysis. The nutritional 
assessment full form is available in Annex A. 
3.3.1. Anthropometry 
Anthropometric measurements were performed according to the 
reference manual ISAK (2011)(37). All participants should be barefoot and 
wearing light clothing during the valuation. Weight was measured using an 
electronic digital scale, with weighing accuracy of 0.1 kg (model 764: Seca 
gmbh & co, Germany), and height was measured with a precision of 1 mm 
(model 764, Seca gmbh & co., Germany). The body mass index (BMI) was 
calculated by dividing body weight (kg) by height² (m), and was classified 
according to the World Health Organization(38). For elderly, we used the 
Nutritional Screening Intervention’s (NSI) cutoff points(39): BMI < 22 
(malnutrition); BMI > 22 and < 27 (normal weight); BMI > 27 (obese) 
Body circumferences were measured with a tape measure, with a 
precision of 1 mm, obtaining the values of arm circumference (AC), waist 
circumference (WC), hip circumference (HC) and calf circumference (CC). 
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Skinfolds were measured with an accuracy of 0.2 mm, with the assistance of a 
calliper (John Bull, British Indicators Ltd, England), obtaining the triceps skinfold 
(TSF), biceps (BSF), subscapular (SCSF), iliac crest (ICSI) and front thigh 
skinfold (FTSF). 
3.3.2. Bioelectrical impedance analysis (BIA) 
The values of resistance (R) and reactance (Xc) were measured at 
800 uA and 50 kHz with an impedance analyzer BIA 101 (Physiological Data 
Analyzer System, Akerne, Florence, Italy), with the subject lying in supine 
position and the electrodes fixed on the right hand and right foot, as described 
in the protocol of Lucaski et al. (40). For measuring the BIA was required a 
minimum 4h of fasting and 24h of caffeine abstinence, and participants should 
withdraw any jewelry and metallic objects. The phase angle (PA) was calculated 
in degrees using the formula: PA = arc tangent (Xc/R)*180/. The body 
composition was measured by Kyle et al.’s BIA formula(41) and given in 
percentage of fat free mass (FFM) and percentage of fat mass (%FM). 
3.4. Adipose tissue quantification  
In order to evaluate the adipose tissue distribution, the patients 
underwent a MDCT scan using a 64-slice computed tomography scanner 
(Somaton Sensation 64, Siemens Medical Solutions, Forchheim, Germany). 
The exam included three different acquirements: the first one for abdominal fat 
quantification, the second one for coronary artery calcification quantification 
(Calcium Score) and the third one for epicardial adipose tissue (EAT) and 
mediastinal adipose tissue (MAT) quantification. All adiposity measures were 
indexed for the body surface area.  
3.4.1. Abdominal fat assessment 
An abdominal single slice acquisition was performed between L4 and 
L5 to assess abdominal fat area as described by Borkan et al. (42). Radiographic 
factors were 120 kV and 216 mAs with 5 mm thickness resulting in an estimated 
radiation exposure of 0.06 mSv. One blinded expert used the obtained slice to 
measure abdominal fat distribution according to the Yoshizumi et al.’s(43) 
method: the adipose tissue was identified in the areas with attenuation values 
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ranging from −150 to −50 Hounsfield Units(44); the total abdominal fat (TAF) 
area was the sum of adipose tissue presented in the examined abdominal slice; 
a cursor pointer was used to trace the visceral abdominal fat (VAF) area by 
delineating the abdominal wall muscular layer. The subcutaneous fat area 
(SAF) was obtained by subtracting VAF from TAF. 
3.4.2. Epicardial adipose tissue (EAT) quantification 
A blinded experienced radiographer quantified EAT volume using a 
cursor pointer to trace manually the pericardial contour, using 1-mm-thick 
reconstructed axial slices. Pericardium contour was traced for every 10 mm 
starting from the lower visible level of pulmonary artery bifurcation until the top 
level of the pulmonary valve for every 20 mm from there until the first slice, 
where the diaphragm becomes visible, and for every 10 mm from this point until 
the last slice, where pericardium is still visible. The pericardium contour is 
extrapolated by the software (Syngo Volume, Siemens Medical Solutions) for 
the non-traced slices and rechecked by the operator. Within these limits, we 
identified EAT using the adipose tissue attenuation references already 
described. We excluded mediastinal adipose tissue and pericardial adipose fat 
(a fat depot outside the visceral pericardium and on the external surface of the 
parietal pericardium) from analysis. 
3.4.3. Mediastinal adipose tissue (MAT) measurement 
Mediastinal adipose tissue was measured by the difference between 
total thoracic fat volume, defined as any adipose tissue located within the thorax 
from the level of the right pulmonary artery to the diaphragm and from the chest 
wall to the descending aorta, and EAT.  
3.5. Cardiac structure and function evaluation. 
All participants were submitted to detailed echocardiographic 
assessment, by a single sonographer, using an ultrasound system (iE33, Philips 
Medical Systems, Best, The Netherlands) equipped with a S5-1 transducer. 
Images were digitally stored for posterior offline analysis. Cardiac chambers 
dimensions, volumes and left ventricular mass were measured according to 
current recommendation(45). All values were indexed to body surface area. The 
doppler echocardiographic indices of AS severity included peak aortic jet 
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velocity, peak and mean transvalvular pressure gradients obtained with the use 
of the modified Bernoulli equation, and the aortic valve area (AVA) calculated by 
the standard continuity equation(46). 
3.6. Clinical evaluation 
All participants were submitted to clinical interview and review of 
medical registries to collect data on cardiovascular risk factors, previous 
medical history, medication use, psychosocial and demographic factors and 
physical daily activities.  
Hypertension was defined as blood pressure above 140/90 mmHg or 
anti-hypertensive drug treatment(47).  
Diabetes was defined as fasting blood glucose  126 mg/dL or anti-
diabetic drug usage(48) and dyslipidemia as total cholesterol > 190 mg/dL or 
currently taking lipid-lowering drugs(49).  
3.7. Statistical analysis 
Studied patients were divided into two groups: frail and non-frail 
patients, with the latter including both robust and intermediate (pre-frail) 
patients. To eliminate the potential body surface area (BSA) confounder effect, 
we used for analysis the measures of fat depots indexed to BSA. Continuous 
variables were described using the mean and standard deviation (SD) if 
normally distributed or median and interquartile range when non-normally 
distributed. Student’s t-test was used for the comparisons between continuous 
variables if normally distributed, and Mann-Whitney U when in cases of non-
normally distributed variables. Categorical variables were described using 
relative frequencies, and compared between frail and non-frail patients using 
the Chi-square test. 
Multivariate logistic regression analysis was used to determine the 
independent association between frailty and indexed EAT volume and indexed 
MAT, VAF, SAF and TAF areas. The association of PA and the indexed fat 
measures were determined using a multivariable linear regression model.  
To eliminate confounding variables we adjusted the regression 
models for 1) all variables statistically significant on the univariate model; and 
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for 2) age and gender. Individual models were created to study the association 
of frailty and PA with each one of the fat depots. The MAT, VAF and SAF 
independent association of frailty and PA with EAT was also assessed. The 
statistical evaluation was performed using SPSS, version 21.0 (SPSS, Inc., 
Chicago, IL) and statistical significance was considered when p < 0.05. 
The sample size was calculated based on data from a previous study 
including HIV-older patients(50) that showed a higher waist circumference in frail  
patients when compared with no frail patients (42±6 versus 37±5 cm). We 
estimated that at least 46 patients (ratio 1:1, n frail=n non-frail=23) are required 
to detect a 12% increase in waist circumference frail patients, with a type II error 
of 20% and a significance level of 5%. We used Stata 13® (StataCorp LP, 
College Station, Texas, USA) to perform the analysis. 
 
Table 1 - Study activities description. 
Activity Variable description Type Variable type Method 
Body fat 
distribution 
assessment 
 EAT volume 
 Mediastinal fat area 
 Total, subcutaneous 
and visceral 
abdominal fat area 
Independent Continuous MDCT 
 Total and 
percentage of body 
fat mass and body 
free fat mass 
Independent Continuous Bioimpedance 
analysis 
 BMI 
 Body 
circumferences: 
ArmC, CalfC, WC, 
HC 
 WC/HC ratio 
 Body skinfolds: TSF, 
BSF, SCSF, ICSF, 
FTSF 
 APMuscle 
Independent Continuous Nutritional 
evaluation 
Frailty Frailty diagnosis Dependent Binary Fried et al. 
(2001)’s scale 
PA Cells membrane integrity 
and function 
Independent Continuous BIA 
Cardiac 
structure and 
function 
 Independent Continuous Echocardiogram 
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APMuscle: adductor Pollicis Muscle; ArmC: arm circumference; BMI: body mass index; BSF: biceps skinfold; CalfC: calf 
circumference; FTSF: front thigh skinfold; HipC: hip circumference; ICSF: iliac crest skinfold; SCSF: subscapular 
skinfold; TSF: triceps skinfold; WaistC: waist circumference; WC/HC: waist circumference/hip circumference ratio. 
4. Results 
4.1. Population characteristics 
Fifty-five patients (mean age of 73±9 years; 57% males) were 
included, with mean BMI of 29±5 kg/m2 (52% of obese) mean %FFM of 
65.2±6.6% and mean %FM of 34.8±6.6%. 
Mean indexed EAT volume was 72 ± 38 mL/m2, and mean indexed 
VAF area was 97±38 cm2. Detailed sample characteristics are shown in Tables 
2 and 3.  
The three visceral fat depots were correlated (Pearson's correlation 
coefficient: 0.53 for EAT vs. MAT, 0.54 for EAT vs. VAF, and 0.55 for MAT vs. 
VAF; p< 0.001 for all). The visceral fat depots were not correlated with SAF 
(Figure 1).  
Figure 1 - Correlation of visceral fat depots. 
 
Figure 1 – Correlation of visceral fat depots.    
The three visceral fat depots were correlated 
to each other, but not with SAF. Pearson's 
correlation coefficient: 0.53 for EAT vs. MAT, 
0.54 for EAT vs. VAF and 0.032 for EAT vs. 
SAF; p< 0.001 for all). 
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4.2. Association of frailty with body fat distribution 
The prevalence of frailty was 47% (26 patients).  
To investigate the association of frailty and measures of global and 
visceral adiposity, we used a multivariable logistic regression model including 
age and gender. In this model, frailty was not associated with BMI, %FFM and 
%FM. We also did not find a significant association with measures of visceral 
abdominal fat (i.e. WC, indexed VAF area and indexed TAF) and with 
mediastinal fat, but there was a significant association between frailty and 
indexed EAT volume (p=0.042).  
Adjusting for age and gender, the odds of frailty increased 4.1-fold 
(95 % confidence interval of 1.03 to 16.4) per additional 100 cm3/m2 of EAT. 
Frailty remained independently associated with EAT after further 
adjustment for SAF (p=0.045), but was attenuated after the inclusion of VAF in 
the model (p=0.056).  
The age and gender adjusted associations of frailty and body fat 
distribution parameters are shown in Table 4.  
4.3. Association of frailty with phase angle 
Frail patients had a significantly lower PA than non-frail patients 
(3.9±0.7 vs. 4.5±1.2, p=0.02) and in a univariate logistic regression analysis, the 
odds of frailty duplicated when the PA decreased 1 degree (Figure 2).  
Adjusting for gender, patients with narrow PA (lowest quartile, 
PA<3.4º) had 5.9-fold higher odds of frailty (95 % confidence interval of 1.2 to 
30.7) when compared with the highest quartile (PA ≥ 4.8º). However, when 
adjusting for age and gender this association declined (p=0.08). 
Since age was correlated with PA (Pearson's correlation coefficient: -
0.54, p<0.001) (Figure 2), and it is a known intermediate variable in the 
pathophysiological process of frailty, the inclusion of this independent variable  
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Table 2 - Comparison of clinical, laboratorial and echocardiographic characteristics 
between frail and non-frail groups. 
 
Results are presented as means ± SD. 
p values shown compare frail and non-frail groups.  
* median (IQR) 
AVAi: aortic valve area index 
HDL: high-density Lipoprotein Cholesterol  
hsCTNT: high-sensitive Cardiac T troponin 
LAVI: left atrium volume index 
LDL: low-density Lipoprotein Cholesterol 
LVEDVi: left ventricular end diastolic volume index 
LVMi: left ventricular mass index 
LVEF: left ventricular ejection fraction 
NT-Pro-BNP: NT-Pro-brain Natriuretic Peptide 
RAVI: right atrium volume index 
TAPSE: tricuspid annular plane systolic excursion 
 
  
  
Frailty Classification 
 
 
 
 
All 
(n=55) 
 Frail 
(n=26) 
Non-frail 
(n=29) 
 
p value 
 
Age, years 72.8±9.4  74.1±9.3 71.0±9.2  0.212  
Male sex, n (%) 35 (57.4)  14 (53.8) 21 (60.0)  0.283  
Hypertension, n (%) 45 (81.8)  20 (76.9) 25 (86.2)  0.373  
Diabetes, n (%) 16 (29.1)  6 (23.1) 10 (34.1)  0.352  
Dyslipidemia, n (%) 43 (78.2)  19 (73.1) 24 (82.8)  0.385  
Laboratory evaluation        
hsCTNT, ng/dL* 0.01(0.02)  0.012 (0.01) 0.013 (0.03)  0.880  
NT-Pro-BNP, pg/mL* 308.0 (748.0)  317.0 (704.0) 206.0 (383.5)  0.058  
Reactive C-Protein,  
mg/dL* 
0.19 (0.38)  0.22 (0.49) 0.11 (0.26) 
 
0.082 
 
Total cholesterol, 
mg/dL* 
162.5 (59.5)  147.0 (62.5) 170.0 (49.5) 
 
0.101 
 
Tryglicerides, mg/dL* 101.5 (55.5)  123.0 (62.0) 95.0 (98.5)  0.170  
LDL cholesterol, 
mg/dL* 
87 (57.8)  82.0 (62.0) 91.0 (53.0) 
 
0.170 
 
HDL cholesterol, mg/dL 53.3 (15.2)  47.7 (14.0) 59.4 (15.3)  0.020  
Calcium Score* 249.3 (1082.7)  254.7 (1488.3) 272.0 (922.1)  0.934  
Glucose, mg/dL* 107.0 (35.0)  107.0 (35.0) 97.0 (96.5)  0.486  
Insulin,  uU/mL* 11.0 (14.2)  9.2 (17.2) 17.0 (14.6)  0.297  
Echocardiografic evaluation       
AVAi, cm²/m² 0.4±0.09  0.4±0.07 0.4±0.10  0.828  
LAVI, mL/m² 49,1±12.8  48.9±9.7 49.3±15.2  0.941  
RAVI, mL/m² 24.2±9.5  26.2±12.7 23.3±4.9  0.255  
LVMi, g/m² 130±24  129±28 131±22  0.325  
LVEDVi, mL/m² 55.92±17.4  57.9±15.5 54.1±19.0  0.477  
LVEF, % 63.9±6.2  64.1±7.1 63.7±5.5  0.818  
TAPSE, mm 22.7±5.2  23.4±3.9 22.3±6.0  0.564  
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Table 3 - Comparison of nutritional evaluation and body fat distribution characteristics 
between frail and non-frail groups. 
 
Results are presented as means ± SD. 
p values shown compare frail and non-frail groups. 
* median (IQR). 
APMuscle: adductor Pollicis Muscle; ArmC: arm circumference; BMI: body mass index; BSF: biceps skinfold; CalfC: calf 
circumference; FTSF: front thigh skinfold; HipC: hip circumference; ICSF: iliac crest skinfold; SCSF: subscapular 
skinfold; TSF: triceps skinfold; WaistC: waist circumference; WC/HC: waist circumference/hip circumference. 
EATVi: indexed epicardial adipose tissue volume;  
MATVi: indexed mediastinal adipose tissue volume 
SAFVi: indexed subcutaneous abdominal fat volume 
TAFVi: indexed total abdominal fat volume 
VAFi: indexed visceral abdominal fat 
  
  
Frailty Classification 
 
 
 
 
All 
(n=55) 
 Frail 
(n=26) 
Non-frail 
(n=29) 
 
p value 
 
Anthropometric evaluation       
BMI, Kg/m2 29.4±4.7  29,3±5.0 29.3±4.2  0.976  
ArmC, cm 32.7±2.9  32.2±3.2 33.1±2.6  0,303  
WaistC, cm 100.9±13.2  101.5±12.1 99.6±13.0  0.577  
HipC, cm 103.4±8.1  103.0±9.9 103.3±5.6  0.862  
CalfC, cm 36.7±3.2  36.4±3.9 36.9±2.5  0.566  
WC/HC 0.97±0.09  0.99±0.08 0.96±0.09  0.317  
TSF, mm 18.4±7.6  19.5±7.1 17.5±8.1  0.370  
BSF, mm 10.0±4.6  11.1±4.3 9.1±4,7  0.128  
SCSF, mm 19.7±7.2  20.7±8.1 18.7±6.2  0.328  
ICSF, mm 21.8±7.0  20.1±7.8 23.4±5.6  0.099  
FTSF, mm 20.7±10.9  22.1±11.3 19.3±10.6  0.405  
APMuscle, mm 20.2±4.4  19.6±4.3 20.8±4.5  0.330  
Bioelectrical impedance  analysis evaluation     
Resistance, ohms 473.3±76.6  472.3±72.6 474.2±81.2  0.926  
Reactance, ohms 35.0±11.0  32.2±8.4 37.5±12.5  0.068  
Phase angle, degrees 4.2±1.1  3.9±0.7 4.5±1,2  0.021  
Fat free mass, Kg 48.9±11.1  47.0±11.0 50.3±11.1  0.286  
Fat free mass, % 65.2±6.6  64.3±7.1 66.0±6.2  0.352  
Fat mass, Kg 26.0±7.2  26.2±7.8 25.8±6.8  0.834  
Fat mass, % 34.8±6.6  35.7±7.1 34.0±6.2  0.352  
Multidetector computed tomography evaluation     
EATVi, mL/m²* 72.1 (38.0)  83.5 (50.6) 63.1 (21.1)  0.093  
MATVi, mL/m² 198.0±73.4  203.3±86.3 193.3±61.3  0.644  
TAFVi, cm³/m² 213.0±61.1  222.5±61.5 205.3±60.7  0.334  
VAFVi, cm³/m² 97.0±38.2  98.5±38.6 95.7±38.5  0.801  
SAFVi, cm³/m² 125.7±68.3  124.0±51.0 127.1±80.7  0.874  
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Figure 2 - Association of phase angle with frailty and age. 
 
Figure 2 – Association of phase angle with frailty and age. Frailty was inversely associated with 
PA, frail patients had a significantly lower mean PA than non-frail patients (p=0.03); for each 
degree of increase of PA, the odds of frailty are reduced by half. (Left) Age and PA was 
inversely correlated (r=-0.54, p<0.001). (Right) 
 
Table 4 - Age and gender adjusted association of frailty syndrome and body fat 
distribution parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p values shown compare frail and non-frail groups. 
BMI: body mass index 
WC/HC ratio: waist circumference/hip circumference ratio 
EATVi: indexed epicardial adipose tissue volume;  
MATVi: indexed mediastinal adipose tissue volume 
SAFVi: indexed subcutaneous abdominal fat volume 
TAFVi: indexed total abdominal fat volume 
VAFi: indexed visceral abdominal fat 
  Frailty Syndrome    
  OR CI, 95%  p value  
BMI  1.006 0.890 to 1.137  0.918  
Waist circumference  1.021 0.972 to 1.073  0.412  
WC/HC ratio  400.4 0.114 to 141412  0.150  
% Fat free mass  0.981 0.877 to 1.097  0.738  
% Fat mass  1.019 0.912 to 1.140  0.738  
EATVi  1.014 1.000 to 1.028  0.045  
MATAi  1.000 0.997 to 1.009  0.281  
VAFAi  1.005 0.994 to 1.016  0.397  
SAFAi  1.000 0.995 to 1.005  1.000  
TAFAi  1.000 0.999 to1.015  0.106  
EATVi*MATAi  1.014 0.999 to 1.029  0.063  
EATVi*VAFAi  1.014 1.000 to 1.029  0.056  
EATAi*SAFAi  1.014 1.001 to 1.028  0.042  
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in the model did not enable us to find a significant association between PA and 
frailty. To surpass this statistical problem, we decided to perform a stepwise 
backward conditional multivariable logistic regression analysis including age, 
gender and PA. Using this method, the variable age was the first term removed 
from the equation (p=0.996), followed by gender (p=0.518).PA was the only 
independent variable that remained in the model (p=0.03). 
The cell membrane reactance (32.2±8.4 vs 37.5±12.5 ohms, 
p=0.068) tended to be inversely associated with frailty but not the cell 
membrane resistance.  
The crude and adjusted association of phase angle quartiles and 
frailty are shown in Table 5. 
Table 5 - Crude and adjusted association of phase angle quartiles and frailty. 
 
 
PA Quartiles in degrees: 1st [2.79; 3.4[; 2nd [3.4; 4.0[; 3rd [4.0; 4.8[; 4th [4.8; 7.19].  
p value for the comparison between PA quartiles using the 4th quartile as the reference category 
 
 
 
4.4. Association of phase angle and body fat distribution 
After observing a significant association of frailty with EAT and of 
frailty with PA, we studied the correlations of PA with body fat distribution 
parameters.  
In an adjusted age and gender linear regression model, PA was 
inversely correlated with WC/HC ratio (r= -0.61, p=0.02), %FM (r= -0.60, 
p=0.02) and indexed EAT volume (r= -0.59, p=0.03), but not with BMI, WC, 
%FFM, indexed MAT, VAF, SAF and TAF areas.  
 
 
Crude 
 
Adjusted for gender 
 Adjusted for gender and 
age 
 
  OR, 95% CI P value  OR, 95% CI P value  OR, 95% CI P value  
           
1st quartile  
6.2, 1.2 to 
32.2 
0.028 
 5.9, 1.2 to 
30.7 
0.036  5.7, to 0.8 to 
39.9 
0.078  
           
2nd quartile  
2.1, 0.4 to 
10.5 
0.348 
 2.1, 0.4 to 
10.5 
0.350  2.1, 0.6 to 
12.0 
0.408  
           
3rd quartile  
1.9, 0.4 to 
9.0 
0.433 
 1.8, 0.4to 
8.9 
0.449  1.8, 0.4to 
9.0 
0.461  
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Adjusting for age, gender, and VAF there was still a significant 
association between PA and indexed EAT volume, with a PA decrease of 8% 
per additional 10 mL/m2 of EAT (p=0.041).  
The associations of PA and body fat distribution parameters are 
shown in Table 6.  
 
Table 6 - Age and gender adjusted association of phase angle and body fat distribution 
parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p values shown compare frail and non-frail groups. 
BMI: body mass index 
WC/HC ratio: waist circumference/hip circumference ratio 
EATVi: indexed epicardial adipose tissue volume;  
MATVi: indexed mediastinal adipose tissue volume 
SAFVi: indexed subcutaneous abdominal fat volume 
TAFVi: indexed total abdominal fat volume 
VAFi: indexed visceral abdominal fat 
 
5. Discussion 
In this observational, cross sectional study including patients with 
symptomatic severe AS referred to MDCT before AVR, we demonstrated that 
(1) EAT was an independent predictor of frailty, but not BMI, WC or VAF; (2) 
Narrow PA was associated with frailty independently of age and gender, and (3) 
EAT, contrarily of VAF, appeared to be associated with impaired cell membrane 
integrity and function assessed by BIA derived PA. 
  Phase angle    
  Beta CI, 95%  p value  
BMI  -0.018 -0.073 to 0.037  0.506  
Waist Circumference  -0.018 -0.040 to 0.003  0.093  
WC/HC ratio  -4.04 -7.390 to -0.680  0.019  
% Fat free mass  -0.004 -0.048 to 0.041  0.866  
% Fat mass  -0.040 -0.074 to -0.007  0.019  
EATVi  -0.008 -0.015 to -0.001  0.026  
MATAi  -0.003 -0.007 to 0.001  0.107  
VAFAi  -0.003 -0.011 to 0.005  0.508  
SAFAi  -0.001 -0.006 to 0.003  0.497  
TAFAi  -0.002 -0.007 to 0.003  0.463  
EATVi*MATAi  -0.007 -0.015 to 0.009  0.086  
EATVi*VAFAi  -0.008 -0.016 to 0.000  0.041  
EATAi*SAFAi  -0.008 -0.015 to -0.001  0.031  
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5.1 Frailty was independently associated with EAT, but not with abdominal 
visceral fat or global adiposity 
Currently, it remains to be elucidated how overweight or obesity 
correlates with frailty. In our study, BMI was not an independent predictor of 
frailty in patients with severe AS. Blaum et al.(51) associated the excess of 
weight assessed by BMI with the pre-frailty phenotype, and the obesity with 
both pre-frailty and frailty, suggesting a positive association between body fat 
and frailty. Hubbard et al.(52) found an interesting U-shaped association between 
BMI and frailty. These authors determined the association of BMI categories 
with the frailty index (FI), which is a proportion (i.e. range from 0 to 1) of the 
summed individual’s deficit divided by the total number of deficits considered (in 
this case, 58). FI scores were lowest in those with BMI ranging from 20 to 29.9 
kg/m2 (normal weight and overweight participants) and higher in those 
underweight and obese (BMI<20 kg/m2 and BMI>30 kg/m2, respectively). The 
limitations of BMI are well recognized(53, 54). The sensitivity of the most used 
cutoff value for obesity (BMI>30 kg/m²) for identifying excessive adiposity is low, 
missing about half of persons with excess body fat, who have BMI values <30 
kg/m²(55). Moreover, BMI does not distinguish if the body fat accumulation 
occurs in the subcutaneous or visceral compartment. To fill this gap, WC has 
been used as an estimative of VAF and WC/HC ratio as a relationship between 
visceral and subcutaneous adipose tissue(56, 57). Visceral fat has stronger 
endocrine activity and inflammatory characteristics than subcutaneous adipose 
tissue(58), having a major role in the pathophysiology of the metabolic 
syndrome(59).  
Our sample size was powered to detect WC differences between frail 
and non-frail patients based on data from Shah et al.(50). In this work including 
HIV-patients with mean age of 58±5 years old, the authors showed a 
significantly higher WC in frail patients when compared with those non-frail. 
Contrarily, in our cohort of 55 patients with severe AS, WC was not associated 
with frailty, as well as the intra-abdominal visceral adipose tissue. The 
lipodystrophy present in HIV-patients could explain this divergent result. 
However, this finding is congruent with our observation that intra-abdominal 
visceral adipose tissue determined by MDCT was not associated with frailty as 
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well. Indeed, in our study only increased EAT was significantly associated with 
frailty, independently of age, gender and body superficies area. 
EAT is the visceral fat located between the myocardium and the 
visceral pericardium, and it has the same embryological origin of the abdominal 
visceral adipose tissue(60).  
Increased visceral abdominal fat and EAT have been both 
associated with metabolic syndrome components(61, 62), coronary artery disease 
(CAD)(62, 63), left ventricular hypertrophy(64, 65) and diastolic dysfunction(66, 67). As 
the visceral abdominal fat, EAT is a source of several inflammatory mediators in 
high-risk cardiac patients, being linked with high levels of TNF-alfa, monocyte 
chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-1 (IL-1) and 
plasminogen activator inhibitor-1 (PAF-1)(68, 69).  Although EAT is highly 
correlated and share similar biochemical properties and adipokines production 
with VAF(70-72), it has been speculated that EAT and VAF may play differential 
physiological and pathological roles given its different anatomical location and 
particular lipolysis and lipid mobilization features.  
Under physiological conditions, earlier studies showed that the rate 
of free-fatty-acid synthesis, breakdown and release in response to 
catecholamines in EAT were markedly higher than in other visceral adipose 
depots. This high lipolysis observed in EAT suggests that EAT may have a 
special function of supplying cardiac muscle with free fatty acids(73). Moreover, 
recent studies showed that EAT associates with coronary atherosclerotic 
burden(74, 75) and with worse diastolic function(67) independently of VAF. 
Interestingly, Mazurek et al.(68) found no correlation between inflammatory 
signals from EAT and plasma inflammatory biomarkers, with no attenuation of 
these signals by chronic treatment with conventional cardiovascular therapies, 
suggesting that the current drug treatment does not eliminate local inflammatory 
indicators in EAT. 
These evidences suggest that EAT has a more relevant local than 
systemic effects. Its close proximity with the cardiac structures provides 
conditions for a direct crosstalk between EAT, the myocardium and the 
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endothelial cells through the release of proatherosclerotic, proinflammatory and 
profibrotic adipocytokines that can modulate, by paracrine and vasocrine 
mechanisms, the coronary arteries endothelial cells and the cardiomyocytes, as 
well as the cardiac stromal cells. 
With ageing process, there is an expansion of the EAT, the number 
of myocytes decreases while the remaining individual myocytes hypertrophy, 
and there is an intracellular lipid accumulation(76). In skeletal muscle, there is an 
increased fat muscle infiltration with an underling chronic inflammation, which 
leads to a decreased muscle quantity and quality. This phenomenon is called 
sarcopenia(77). Ultimately, EAT is “the cardiac muscle fat”, with a paracrine 
inflammatory regulation, hence it is expected that the same sarcopenia process 
occurs in cardiac muscle. This new concept is currently called “cardiac 
sarcopenia”. 
Therefore, the process linking EAT and frailty could follow the 
sequence: (1) a local compensatory mechanism: the EAT increases to feed the 
cardiac tissue during the catabolic state typically present in cardiac diseases; 
(2) increased EAT and the catabolic state itself enhance the release of 
inflammatory mediators to the myocardium; and (3) the lipid accumulation and 
the excess of inflammatory mediators could lead to cardiac sarcopenia, which 
could lead to frailty and restart the cycle. 
5.2 PA as a marker of frailty and EAT-related inflammation 
The role of PA as a marker of nutritional status, impaired clinical 
outcomes and mortality in populations with chronic disease is widely 
recognized(31-33). However, the relation between PA and frailty is little explored. 
Wilhelm-Leen et al.(78) found a significant association between PA and frailty, 
which remained significant even when adjusted for age, sex, race-ethnicity and 
comorbidity in 4.667 community American older adults. In cardiac surgical 
patients, a low PA was associated with less muscle mass and strength and with 
prolonged intensive care unit and hospital stay length(79). In this work we found 
that patients with a narrow PA (lowest quartile, PA<3.4º) had 5.9-fold higher 
odds of frailty (95 % confidence interval of 1.2 to 30.7) when compared with 
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patients in the highest quartile (PA ≥ 4.8º). This finding supports the idea that 
PA could be used as a biomarker to diagnose and to grade frailty in the 
preoperative risk assessment of patients with AS.  
There is sparse data evaluating how different fat depots affect the 
overall cell membrane integrity and function. Our study showed that EAT was 
the only fat depot significantly associated with PA. Narrow PA was associated 
with higher indexed EAT volume even when adjusted for age, gender, VAF, 
%FFM and %FM. 
As narrow PA correlates with high levels of inflammation markers(30, 
80) and impaired cellular membrane(26), our results demonstrate that the amount 
of EAT is more closely linked to cellular health than VAF in patients with AS. 
Our findings corroborate Mazurek’s et al. study(68), which demonstrated that 
proinflammatory properties of EAT were independent of BMI, diabetes or 
chronic therapy with statins or angiotensin converting enzyme inhibitors in 
patients with coronary artery disease.  
To the best of our knowledge, only one study correlates PA with 
EAT, however the authors found opposite data(81). In this study the authors 
compared the association of EAT and PA in patients with ischemic and non-
ischemic cardiomyopathy with reduced ejection fraction (<35%) with heathy 
controls. The main findings were that EAT and PA were lower in patients with 
heart failure in comparison to healthy controls, irrespective of its etiology. 
Doesch et al.(82) showed that the amount of EAT differs according to 
the left ventricular ejection fraction (LVEF) in patients with CAD. Patients with 
CAD and preserved LVEF had significantly more EAT than healthy controls and 
patients with reduced LVEF. Then, in patients at an early stage of the coronary 
disease, EAT is increased, but with disease progression there is a reduction of 
this fat depot. In line with this observation, since we restricted our sample to 
patients with preserved ejection fraction, our positive association between PA 
and frailty and negative association of PA and EAT suggests that this BIA 
derived value could be a marker of frailty and EAT-related decline of cellular 
function. 
5.3 Limitations and strengths 
 The strengths of this study are:  
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1) We studied a homogenous cohort of patients with AS regarding 
its heart disease severity; 
2) We quantified fat by MDCT and a detailed nutritional assessment 
was performed; 
3) Frailty was determined using a validated scale for cardiovascular 
patients. 
However, same limitations should be noted:  
1) We did not include a control group; 
2) The cross-sectional design prevent us from determining the long-
term influences of frailty and PA in this population, especially in 
patients who undergo surgery and the cause-and-effect 
relationship between greater amount of EAT and frailty; 
3) Also, our sample size may not have been large enough to pick up 
differences among groups in some variables, as well as the lack 
of a control group prevent us to identify differences between our 
sample and a healthy population; 
4) In addition, although our patients are in the same level of 
impaired cardiac function, we do not know the previous influence 
of the cardiac disease in the development of a frailty state or in 
body composition; 
5) Beyond the ejection fraction, we should have used more sensitive 
parameters to evaluate the cardiac function, for instance doppler 
echocardiography; 
6) The localized MDCT used to access the abdominal obesity do not 
describe the total trunk fat, which could influence our results; 
7) Finally, we did not obtain laboratorial analysis of all patients, 
preventing us from correlate EAT, PA and frailty with metabolic 
syndrome, insulin resistance and inflammatory markers in this 
population. 
6. Conclusions 
In patients with severe AS, there are ongoing efforts to better identify 
the patient with high perioperative risk of death since these patients should be 
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referred to transcatheter aortic valve implantation rather than surgical 
replacement. The current perioperative risk scores (i.e. EuroScore II(83) and STS 
score(84)) do not consider the frailty phenotype features. Recent guidelines on 
the management of valve disease from the American Society of Cardiology 
recommend the evaluation of frailty before surgery(85). However, none of the 
frailty models is currently feasible for widespread clinical application.  
This study highlights that increased indexed EAT as well as a low PA 
might be surrogate markers of frailty in patients with severe AS and preserved 
ejection fraction. Then, in these patients, the additional preoperative EAT and 
PA determination could contribute to a better diagnose and grade of frailty.  
These results show that the subjective evaluation of frailty usually 
performed in clinical practice is not reliable, since it is typically based in BMI and 
central adiposity.   
The intersection of body composition analysis and frailty is an 
important area of research with much to explore. Future research should focus 
on longitudinal data that demonstrate how preoperative PA and EAT predict 
clinical outcomes after surgery, including the frailty syndrome recovery. It 
remains to be demonstrated if and how EAT volume and PA change after 
surgery and what will be its prognostic implications.  
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Nutricional 
 
 
 
 
 
 
 
NÚMERO DO DOENTE [ID] 
   
 
 
EpicHEART 
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Dados Pessoais 
Data da avaliação: 
Data de Nascimento: Sexo: 
Escolaridade: 
Profissão: 
Uso de tabaco: Qtde/dia: 
Uso de álcool: Qtde/dia: 
Diabetes: 
Hipertensão: 
Hipercolesterolemia:  
Ativ. Física: Frequência: 
Uso de suplementos: Duração: 
Avaliação Nutricional 
Peso: 
Altura: 
IMC: 
Circunferências 
C. Braço: _____________________ 
C. Cintura: ____________________ 
C. Quadril: ___________________ 
C. Geminal: ___________________ 
Pregas Cutâneas: 
PC Tricipital: _________________ 
PC Bicipital: __________________ 
PC Subescapular: _____________ 
PC Iliocristal: __________________ 
PC Coxa Medial: _______________ 
M. Adutor Polegar: _____________ 
Bioimpedância: 
Resistência: __________________ 
Reatância: ___________________ 
Ângulo de fase: _______________ 
% Massa Gorda: ________________ 
% Massa Magra: ________________ 
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Escala de Fragilidade (Fried et al., 2001) 
Perda de Peso: 
Pergunta-se: “no último ano, você perdeu peso de forma não 
intencional, ou seja, sem fazer dieta ou atividade física com esse objetivo?” Em 
caso de resposta positiva, pergunta-se quantos quilos. São considerados 
frágeis aqueles que relatam perda superior a 4,5kg ou 5% do peso corporal. 
Fadiga: 
Baseado na escala de depressão do Center for Epidemiological 
Studies-Depression (CES-D), as duas sentenças seguintes são lidas: 
1. Senti que eu fazia tudo com um esforço. 
2. Eu não consegui continuar / tive que parar. 
Então pergunta-se: “com que frequência você se sentiu assim na 
última semana? 
0 = nunca ou raramente (<1 dia) 
1 = pouco tempo (1–2 dias) 
2 = um tempo razoável (3-4 dias) 
3 = a maior parte do tempo. 
Pacientes com respostas 2 ou 3 são caracterizados como frágeis no 
critério fadiga. 
Velocidade da marcha: 
O idoso deve percorrer em passo usual, no plano, uma distância de 
4,6m. 
Homens Ponto de Corte para Fragilidade 
Força de Preensão da Mão: ____________/_____________/__________ 
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Altura ≤ 173 cm ≥ 7 segundos 
Altura > 173 cm ≥ 6 segundos 
Mulheres  
Altura ≤ 159 cm ≥ 7 segundos 
Altura > 159 cm ≥ 6 segundos 
 
Força de preensão manual: 
Medida com dinamômetro colocado na mão dominante de cada 
idoso, em três tentativas, respeitando um minuto de intervalo entre elas. 
Homens Ponto de Corte para Fragilidade  
IMC ≤ 24 Kg/m² ≤ 29 Kg 
IMC 24,1 – 26 Kg/m² 
IMC 26,1 – 28 Kg/m² 
IMC > 28 Kg/m² 
≤ 30 Kg 
≤ 30 Kg 
≤ 32 Kg 
Mulheres  
IMC ≤ 23 Kg/m² ≤ 17 Kg 
IMC 23,1 – 26 Kg/m² 
IMC 26,1 – 29 Kg/m² 
IMC > 29 Kg/m² 
≤ 17,3 Kg 
≤ 18 Kg 
≤ 21 Kg 
 
Atividade Física  
Pacientes com gasto energético ligado à atividade física <383 
kcal/semana, para mulheres, e <270 kcal/semana, para homens, são 
considerados como frágeis no critério atividade física. 
IAM = ∑ (I x M x F x T), onde IAM = gasto energético; I = intensidade 
de cada atividade física em METS; M = número de meses/ano em que a 
atividade foi realizada; F = número médio de vezes que foi realizada no mês; T 
= duração média da atividade em cada ocasião. Para obter o valor em kcal: I x 
0,0175 x Peso (kg). 
Classificação final: 
0 componentes  sem fragilidade 
1 ou 2 componentes  risco de fragilidade 
3 ou mais componentes  fragilidade 
